Breast Cancer Research and Treatment

Article	Citations
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer	95
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies	72
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment	67
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018	66
International variation in breast cancer incidence and mortality in young women	65
Body composition and breast cancer risk and treatment: mechanisms and impact	57
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer	50
Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors	50
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)	44
PIK3CA-mutations in breast cancer	42
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early	41
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial	38
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer	38
Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis	36
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol	34
Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis	34
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial	34
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis	34
Immunotherapy toxicity: identification and management	33
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT	30
Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy	30
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific sub	29
A systematic review of multimodal prehabilitation in breast cancer	28
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer	28
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population	27

Clinical trials of immunotherapy in triple-negative breast cancer	27
A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation	27
The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer	27
Advances in the prevention and treatment of breast cancer-related lymphedema	26
ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells	26
Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients	25
Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer	25
Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors	25
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic	24
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	24
Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model	23
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients	23
The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review	23
Characterization of estrogen receptor-low-positive breast cancer	23
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research	23
Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients	23
Breast cancer resistance mechanisms: challenges to immunotherapy	23
Implications of missing data on reported breast cancer mortality	23
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer	23
Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells	23
Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer	23
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer	22
The WISDOM study: a new approach to screening can and should be tested	22
Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up	22
Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile	22
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)	22
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation	22
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer	21
COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic	21
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system	21
A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity	21
NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis	21
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer	21
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase	21
Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer	20
Tumor subtypes and survival in male breast cancer	19
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function	19
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer	19
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey	19
Presentation and characteristics of breast cancer in young women under age 40	19
LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis	19
SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study	19
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors	19
Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis	19
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer	18
FASN inhibition as a potential treatment for endocrine-resistant breast cancer	18
Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017	18
Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis	18
Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing	18
Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis	18

Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population	17
Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach	17
Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial	17
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review	17
Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells	17
Breast cancer vaccines for treatment and prevention	17
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant system	17
Covid-19 related oncologist’s concerns about breast cancer treatment delays and physician well-being (the CROWN study)	17
Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial	17
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer	17
The epithelial sodium channel has a role in breast cancer cell proliferation	16
Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging	16
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies	16
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metasta	16
Standardization of the tumor-stroma ratio scoring method for breast cancer research	16
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer	16
Clinical trial data and emerging strategies: HER2-positive breast cancer	16
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations	16
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer	16
Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer	16
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells	16
The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer	16
Escalating de-escalation in breast cancer treatment	15
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?	15
High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer	15
An overview of genetic services delivery for hereditary breast cancer	15
Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade	15
Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes	15
Association of mammographic density measures and breast cancer “intrinsic” molecular subtypes	15
Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer	15
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer	15
Risk factors for breast cancer subtypes among Black women undergoing screening mammography	15
Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?	15
Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression	14
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanc	14
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review	14
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast	14
Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer	14
The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery	14
Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review	14
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer	14
Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials	14
FOXA1 is a determinant of drug resistance in breast cancer cells	14
Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study	14
COVID-19 vaccination and breast cancer surgery timing	14
Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy	14
Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer	14
Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery	14
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis	14
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients	14
Impact of molecular subtype and race on HR+, HER2− breast cancer survival	13
Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)	13
Low RAI2 expression is a marker of poor prognosis in breast cancer	13
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer	13
Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen	13
A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density	13
Breast cancer immune microenvironment: from pre-clinical models to clinical therapies	13
Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast	13
Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines	13
Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study	13
Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers	13
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer	13
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review	13
Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?	13
Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity	13
Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer	13
N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target	13
Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis	13
Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers	13
Overcoming disparities: Multidisciplinary breast cancer care at a public safety net hospital	13
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles	13
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer	13
The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements	13
Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation	12
M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma	12
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer	12
Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer	12
(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic	12
The dynamics of HER2-low expression during breast cancer progression	12
Associations between frailty and cancer-specific mortality among older women with breast cancer	12

Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer	12
Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidenc	12
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells	12
Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein	12
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975	12
Factors associated with late risks of breast cancer-specific mortality in the SEER registry	12
Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study	12
Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series	12
International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients	12
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers	12
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial	12
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer	12
The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials	12
Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy	11
Biomarkers of immunotherapy response in breast cancer beyond PD-L1	11
Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer	11
Brief relaxation training is associated with long-term endocrine therapy adherence among women with breast cancer: post hoc analysis of a randomized controlled trial	11
Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue	11
Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population	11
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer	11
Postmenopausal overweight and breast cancer risk; results from the KARMA cohort	11
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study	11
Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication bet	11
Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB)	11
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival	11
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial	11
Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography	11
Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial	11
Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention	11
Prosigna test in breast cancer: real-life experience	11
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	11
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, d	11
Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea	11
Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE)	11
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative br	11
Association between lincRNA expression and overall survival for patients with triple-negative breast cancer	11
Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers	11
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer	11
Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer	11
Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield	10
Differences in somatic TP53 mutation type in breast tumors by race and receptor status	10
Effects of preoperative magnetic resonance image on survival rates and surgical planning in breast cancer conservative surgery: randomized controlled trial (BREAST-MRI trial)	10
Immediate breast reconstruction in locally advanced breast cancer: is it safe?	10
Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study	10
Associations of one-carbon metabolism-related gene polymorphisms with breast cancer risk are modulated by diet, being higher when adherence to the Mediterranean dietary pattern is low	10
The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta-analysis	10
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer	10
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer	10
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian populatio	10
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial	10
Axilla lymph node dissection can be safely omitted in patients with 1–2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis	10
Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?	10
The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer	10
Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability	10
Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer	10
Call to action: breast cancer screening recommendations for Black women	10
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA	10
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period	10
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer	10
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer	10
Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case–control study	10
B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis	10
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics	10
Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017	10
Male and female breast cancer: the two faces of the same genetic susceptibility coin	10
COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation	10
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS	10
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer	10
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin	10
Breast cancer risk prediction combining a convolutional neural network-based mammographic evaluation with clinical factors	9
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study	9
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction	9
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer	9
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk	9
Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI	9
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience	9
HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines	9
Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer	9
Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study	9
Penetrance of male breast cancer susceptibility genes: a systematic review	9
Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens	9
Survival of women diagnosed with breast cancer and who have survived a previous cancer	9
New horizons in imaging and surgical assessment of breast cancer lymph node metastasis	9
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq	9
Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial	9
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy	9
SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast	9
Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer	9
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES	9
Contrast enhanced mammography in breast cancer surveillance	9
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial	9
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study	9
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis	9
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging	9
Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation	9